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Abstract
Background: Recent studies suggest that betaKlotho (KLB) and endocrine FGF19 and FGF21 redirect FGFR signaling to
regulation of metabolic homeostasis and suppression of obesity and diabetes. However, the identity of the predominant
metabolic tissue in which a major FGFR-KLB resides that critically mediates the differential actions and metabolism effects of
FGF19 and FGF21 remain unclear.
Methodology/Principal Findings: We determined the receptor and tissue specificity of FGF21 in comparison to FGF19 by
using direct, sensitive and quantitative binding kinetics, and downstream signal transduction and expression of early
response gene upon administration of FGF19 and FGF21 in mice. We found that FGF21 binds FGFR1 with much higher
affinity than FGFR4 in presence of KLB; while FGF19 binds both FGFR1 and FGFR4 in presence of KLB with comparable
affinity. The interaction of FGF21 with FGFR4-KLB is very weak even at high concentration and could be negligible at
physiological concentration. Both FGF19 and FGF21 but not FGF1 exhibit binding affinity to KLB. The binding of FGF1 is
dependent on where FGFRs are present. Both FGF19 and FGF21 are unable to displace the FGF1 binding, and conversely
FGF1 cannot displace FGF19 and FGF21 binding. These results indicate that KLB is an indispensable mediator for the
binding of FGF19 and FGF21 to FGFRs that is not required for FGF1. Although FGF19 can predominantly activate the
responses of the liver and to a less extent the adipose tissue, FGF21 can do so significantly only in the adipose tissue and
adipocytes. Among several metabolic and endocrine tissues, the response of adipose tissue to FGF21 is predominant, and
can be blunted by the ablation of KLB or FGFR1.
Conclusions: Our results indicate that unlike FGF19, FGF21 is unable to bind FGFR4-KLB complex with affinity comparable to
FGFR1-KLB, and therefore, at physiological concentration less likely to directly and significantly target the liver where FGFR4-
KLB predominantly resides. However, both FGF21 and FGF19 have the potential to activate responses of primarily the
adipose tissue where FGFR1-KLB resides.
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Introduction
The diverse FGF homologues constitute a large family of 22
distinct proteins in human that sense environmental cues to
regulate cellular and metabolic homeostasis [1,2,3,4,5]. Their
transmembrane receptor tyrosine kinase FGFR family encoded by
4 genes contains a plethora of isoforms through combinatorial
alternative splicing of their gene products [5,6], among which are
the principal IIIb and IIIc isoforms for FGFR1–3 but not FGFR4.
With heparan sulfate glycan motifs as the cofactor, the canonic
FGFs including FGF1–10, 16–18, 20 and 22 are predominant for
cell growth, survival, differentiation and migration that when
aberrant may drive cancer progression [5,7]. With the assistance
from transmembrane cofactors Klotho (KL) and betaKlotho
(KLB), the endocrine FGF19 subfamily including FGF19, 21
and 23 play important roles in control of bile acid synthesis and
systemic lipid, glucose, energy and minerals metabolic homeostasis
[8,9,10,11].
Unlike the canonic FGFs that possess high affinity for matrix
heparan sulfate (HS) motifs [5,7,12,13,14,15] and thus act only
locally as autocrine and paracrine factors, the FGF19 subfamily
has extremely low affinity for HS, which permits their circulation
as endocrine hormones to distal tissues/organs where the FGFR
and KL or KLB are co-expressed [16,17]. KL and KLB are single
transmembrane domain proteins containing tandem glycosidase
domains of unknown functions in the extracellular region and
short intracellular tails [18,19,20]. KLB is expressed in liver,
adipose tissue, pancreas and muscle, and KL in kidney and
intestine [18,21,22,23]. It has been thought that the endocrine
effects of these hormonal FGFs are determined by expression
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patterns in adult tissues of themselves, FGFRs and cofactor KL/
KLB, and by their specific interactions with different combinations
of FGFRs and KL/KLB that then form productive signaling
complexes. The postprandial FGF19 (FGF15 in mice) is produced
in ileum under the regulation of nuclear farnesoid X receptor
(FXR), and thought to act in liver hepatocytes where FGFR4-KLB
resides to negatively regulate bile acids synthesis [8,21,24].
Vitamin D and the vitamin D receptor regulate the expression
of FGF23 in bone that in turn negatively regulates minerals
metabolism in the kidney that expresses FGFR1 and KL [10].
As the FGF19, FGF21 has been reported to regulate glucose
and lipid metabolism and energy balance [25,26]. Treatment with
FGF21 corrects metabolic disorders such as hyperglycemia,
hyperlipidemia and insulin resistance in rodent and primate
models of diabetes and obesity [27,28,29,30]. However, the
predominant endocrine axis in which FGF21 is produced in one
tissue and then targets the other tissues underlying these beneficial
effects is not clearly understood. It is reported that FGF21 is
induced preferentially in the liver under the control of PPARa in
response to fasting, ketogenic diet and in type 2 diabetes and
obesity [31,32,33,34,35]. It is also expressed in some extra-hepatic
metabolic and endocrine tissues. In white adipose tissues and
cultured adipocytes, FGF21 expression is upregulated by PPARc
agonist or under conditions including fasting and high fat diet
feeding [36,37,38]. Skeletal muscle or cultured muscle cells were
reported to express and secrete FGF21 under insulin stimulation
and dependent on AKT1 pathway [39,40]. Thermogenic
activation can induce brown adipose tissue to express FGF21
under ATF2 control [41]. Adult thymus may also expresses
FGF21 [42]. On the other hand, several tissues have been implied
as the potential targets of FGF21 action. Most reports suggested
that in adipocytes and white fat, FGF21 stimulates glucose uptake
via upregulation of GLUT1 expression [28,36], but were
discrepant on whether it stimulates or inhibits lipolysis
[28,43,44,45]. Several reports in FGF21 transgenic and knock-
down mice demonstrated that FGF21 may play a role in the
physiological response of the liver to fasting and ketogenic diets
through stimulating ketogenesis and triglycerides clearance in the
liver [33,46,47], but other studies such as with FGF21 ablation did
not confirm the observations in the liver and suggested that FGF21
primarily stimulates lipolysis during fed state but inhibits upon
fasting in white fat [44]. The effects of FGF21 in the liver are
assumed through an autocrine or paracrine action that controls
ketogenesis [31,33,48], glycemia via regulating glucose flux and
insulin sensitivity [27] and gluconeogenesis through induction of
PGC-1alpha expression during prolonged fast [47]. FGF21 may
also improve pancreatic b-cells function and survival [49],
stimulate skeletal muscle glucose uptake [50], stimulate thermo-
genesis of brown fat by increasing the expression of thermogenic
genes and enhancing the total and uncoupled respiration and
glucose oxidation [32], and stimulate the hypothalamus or central
nervous system for energy expenditure and reduction of obesity in
rat DIO model [51].
FGFR1 and FGFR4 are two major receptor isotypes implicated
by the majority of reports in the action of endocrine FGF21 and
FGF19. FGFR1 is predominantly expressed in adipose tissue and
adipocytes, and FGFR4 is predominantly in the liver and
hepatocytes, all of which co-express the KLB [17,21,23,52]. As
measured by crude affinity pull-down of ectodomains of FGFRs or
by ERK1/2 activation in vitro, both FGF19 and FGF21 could
bind and activate FGFR1 in the presence of KLB [9,17,23,53,54].
Unlike FGF19, although FGF21 could also bind to FGFR4-KLB
weakly, it was unable to activate FGFR4-KLB and to stimulate the
liver response [17,23,44]. Even though FGF21 is expressed
predominantly in the liver, it could activate the response of fat
tissue or adipocytes but not the liver [17,44]. These results differ
from several reports that suggested the stimulatory activity of
FGF21 for the liver response [27,31,33,47,48]. To better
understand the receptor and tissue specificities of FGF21, which
are the core constituents of its endocrine metabolic pathway, in
comparison to FGF19 and the canonic FGF1, we employed in this
study several approaches including the sensitive radio-labeling and
quantitative cell surface receptor competition binding and
activation, receptor downstream signaling relay and the expression
of the early response gene. We found that in presence of KLB,
FGF19 binds and activates both FGFR1 and FGFR4 to a
comparable extent, while FGF21 binds and activates the FGFR1
that resides in adipose tissues but comparably not the liver
FGFR4. Our results support the idea that among endocrine and
metabolic tissues, hepatic FGF21 directly and preferentially acts
on fatty tissues but less likely or less significantly on the liver.
Results
FGF21 interacts only with FGFR1 with high affinity in
presence of KLB while FGF19 with both FGFR1 and
FGFR4
To gain insights into the receptor and tissue specificity of FGF21
action as compared to FGF19 and canonic FGF1, we first
performed in vitro sensitive and quantitative receptor binding
kinetic analyses. It has been known the direct contact interaction
between transmembrane FGFR1/4 and KLB by mutual affinity
pull-down and identification by nano-LC MS/MS [4,28]. We
found that FGF19 bound equally well to FGFR1-KLB and
FGFR4-KLB, but not to FGFR1 alone although there is 10%
binding to FGFR4 alone consistent with previous report
(Figure 1A) [4]. Covalent affinity cross-linking revealed three
cross-linking bands resulted from 125I-FGF19 bound to FGFR1
and KLB co-expressing cells (Figure 1B, bidirectional arrows),
similar to what we observed in the interaction of 125I-FGF19 with
FGFR4 and KLB, but not with FGFR1 or FGFR4 alone [4]. The
successful covalent affinity crosslinking also indicated that our
recombinant FGF19 was sufficiently active for interaction with
FGFR-KLB (see also Figure 2 described below), similar to FGF1
with or without KLB.
Since iodination with the same procedure appeared to
inactivate FGF21, we used the labeled FGF19 as the binding
tracer and unlabeled FGF21 as a competitor to probe the receptor
binding activity of FGF21. 2 ng/ml of iodinated FGF19 could
make equally detectable binding to that of 2 ng/ml iodinated
FGF1. 1 mg/ml FGF21 competes with 125I-FGF19 for binding to
FGFR1-KLB or KLB alone with over 90% efficiency, indicating
both recombinant FGF19 and FGF21 had comparable activity
towards FGFR1-KLB and KLB. However, at this high concen-
tration there is only 10–20% efficiency for FGF21 to bind FGFR4-
KLB. No competition binding can be detected to FGFR4 alone to
which 10% of 125I-FGF19 bound as compared to FGFR4-KLB
(Figure 1C, bidirectional arrows) [4]. In contrast, although
1 mg/ml unlabeled FGF19 competes with 2 ng/ml 125I-FGF19
completely as predicted, FGF1 had no displacement for 125I-
FGF19 bound to the FGFR1-KLB, FGFR4-KLB, or KLB alone
at 100 ng/ml (Figure 1C) or 1 mg/ml (not shown). The weakly
bound FGF19 to FGFR4 alone can be displaced by 100 ng/ml
FGF1 equally well as FGF19 itself but not FGF21. These results
are consistent with the previous report that, 125I-labeled FGF1
binds equally well to the surface of cells where FGFR4 are present
independent of KLB; in contrast, FGF19 binds to cells that express
FGF21 Activates Preferentially Adipose FGFR1-KLB
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KLB, which include cells co-expressing FGFR4-KLB and cells
expressing KLB alone [4].
It should be noted that the activity of recombinant FGF19 and
FGF21 is comparable to those currently used in other groups
(personal communication). Radio-iodinated FGF19 exhibited an
affinity with a Kd value of 303 pM to the FGFR1-KLB complex
expressed on the T-Rex 293 cells [4] (Fig. 2A), and 778 pM to a
hepatocellular carcinoma cells expressing FGFR4 and KLB [4,8]
(Fig. 2B). The binding affinity constants of FGF19 are 3–7 times
less than those of FGF1 [55], but are better than those from other
experiments [53,54,56]. Since a same iodination procedure
inactivated both mouse and human FGF21, we employed mutual
comparative competition binding assay and iodinated FGF19 to
address their receptor binding ability and specificity; however, it
would be desirable in the next step to overcome this iodination
problem, so the native binding constant can be deduced and
compared to FGF19 in the direct binding assay on cells expressing
endogenous FGFR and KLB.
Dose-dependent competition of FGF21 with FGF19 for
binding to FGFR1-KLB but comparably not to FGFR4-KLB
To determine quantitatively the interaction nature of FGF19 and
FGF21 with FGFR1 and FGFR4, we assessed the dose-dependent
competition of FGF21 with FGF19 for receptor binding. 125I-
FGF19 was co-incubated with graded concentrations of FGF21 on
cells co-expressing KLB and inducible FGFR1 or FGFR4,
respectively [4]. The remaining binding of FGF19 was measured
quantitatively by radio-activity. FGF21 couldn’t compete with 125I-
FGF19 for FGFR4-KLB interaction, with a half-maximum effective
concentration that is out of valid calculation range. In marked
contrast, FGF21 competes for binding to FGFR1-KLB with a half-
maximum concentration of about 150 ng/ml, which is comparable
to 110 ng/ml for unlabeled FGF19 for binding to both FGFR1-
KLB and FGFR4-KLB (Figure 3A).
On the other hand, FGF1 at all concentrations tested couldn’t
compete with 125I-FGF19 for binding to FGFR1-KLB and FGFR4-
KLB (Figure 3A). Conversely, both FGF21 and FGF19 couldn’t
compete with 125I-FGF1 for binding to either FGFR1-KLB
(Figure 3B) or FGFR4-KLB (Figure 3B inset) at all concentrations
tested. This strongly indicates that the biochemical mechanisms
underlying the receptor interaction are likely different between the
heparin-binding canonic FGFs and KLB-binding endocrine FGFs.
Interaction of FGF19 and FGF21 with KLB
One notable feature of FGF19 is its high-affinity binding to
KLB alone but not FGFR alone [4] (Figure 1A). To further assess
Figure 1. Receptor specificity of FGF1, FGF19 and FGF21. (A) Comparative binding properties of FGF19 and FGF1. Parental T-Rex 293 cells and
cells expressing FGFR1-KLB, FGFR1, FGFR4-KLB, FGFR4 and KLB upon 30 ng/ml Tet induction for FGFRs were incubated with 2 ng/ml 125I-labeled
FGF1 (white rectangle) or 125I-FGF19 (black rectangle) as indicated. Cell surface bound radioactivity was determined by c–counter. Data are shown as
mean 6 s.d. of three independent experiments. (B) Covalent Affinity chemical cross-linking was performed as described [4]. Cross-linking bands were
indicated by bidirectional arrows. (C) Receptor binding properties of FGF21 revealed by competition binding with 125I-FGF19. FGF21, FGF19 and FGF1
at 1 mg/ml were incubated in the presence of 2 ng/ml 125I-FGF19 with parental cells and cells expressing FGFR1-KLB, FGFR1, FGFR4-KLB, FGFR4 and
KLB. Specific cell surface binding and statistic analyses were determined as above.
doi:10.1371/journal.pone.0033870.g001
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whether FGF21 has the same ability to bind KLB as FGF19,
graded concentrations of FGF21 were used to compete with 125I-
FGF19 binding to KLB. FGF21 was able to displace 125I-FGF19
from KLB in a dose-dependent manner that is similar to the
unlabeled FGF19; in contrast, FGF1 was unable to do so at all
concentrations determined (Figure 4A). These results are consis-
tent with the role of the C-terminus of FGF19 and FGF21 in the
interaction with KLB [53,54,57], and suggest a mechanism that
endocrine FGFs form complex with FGFRs through in part the
binding to KLB with high affinity but not to HS motifs, while
canonic FGFs need only HS motifs for the complex formation with
FGFRs.
Since our results shown that FGF19 could bind to FGFR4 alone
with 10% efficiency but not FGFR1, we ask whether such a weak
binding to FGFR4 is related to the mechanism of FGF1 binding.
In fact, FGF1 displaced 125I-FGF19 from FGFR4 completely in a
dose dependent manner similar to that of unlabeled FGF19, while
FGF21 was unable to do so (Figure 4B). This is in contrast to the
inability of both FGF19 and FGF21 to displace 125I-FGF1 from
binding to FGFR4, FGFR4-KLB or FGFR1-KLB (Figure 3B).
These data indicates that there may be a fundamental difference
between the canonic FGF1 and endocrine FGF19 or FGF21 in the
interaction with FGFRs, and such a weak FGF19 interaction may
contribute to the receptor selectivity. As the interaction of both
FGF19 and FGF21 with the binary FGFR-KLB complex is
stronger than with KLB, and the N-terminus of FGF21 is
important for interaction with FGFRs measured by the down-
stream ERK1/2 activation but not without the presence of KLB
[53,54], our results suggest that the integration of KLB is the key
mechanism in the productive complex formation for the endocrine
FGF19 and FGF21 with the canonic HS-FGFRs pre-complex
residing across the plasma membrane.
FGF21 activates downstream signaling of FGFR1-KLB but
not FGFR4-KLB
To determine whether the detectable surface receptor interac-
tion leads to receptor downstream signal transduction, we assessed
the downstream ERK1/2 activation in the same T-Rex 293 cells
on which we performed the binding analyses. The ectopic
expressions of FGFR1 and FGFR4 were induced by 10–30 ng/
ml Tet overnight to avoid extensive apoptotic effect in KLB co-
expressing cells [4]. Consistent with the binding profile, FGF1
activates FGFR1-KLB, FGFR1, FGFR4-KLB and FGFR4
equally well but not KLB, and KLB has no inhibitory or
stimulatory effects on FGF1 binding (Figure 1 and 3) and activity
(Figure 5A). FGF19 activates both FGFR1-KLB and FGFR4-KLB
efficiently and FGFR4 alone weakly but not FGFR1 alone as
revealed by FGFR autophosphorylation and pERK1/2
(Figure 5A); while in marked contrast, although FGF21 bound
to FGFR4-KLB very weakly, it could only activate the FGFR1-
KLB expressing cells (Figure 5A), not the FGFR4-KLB, FGFR4 or
FGFR1 expressing cells over the response level of the cells
expressing KLB alone. Both FGF19 and FGF21 activate the KLB-
expressing cells, albeit with a weaker potency, which is consistent
with other reports [17,21] as the T-293 cells expressed the
endogenous FGFR1 at a low level (unpublished observation) [17].
These results further support the idea that FGF21 is likely unable
to activate FGFR4-KLB expressing cells.
To investigate whether the effective receptor binding in
transfected T-293 cells represents biological or physiological
interactions, and therefore, activities, we determined the biological
responses of cells expressing the endogenous FGFR and KLB to
FGF19 and FGF21 stimulation with a comparable concentration
used in the aforementioned binding assays. In differentiated 3T3-
L1 adipocytes that co-express predominantly the FGFR1-KLB,
FGF19, FGF21 and FGF1 activate the ERK1/2 to an equal
extent, while in hepatoma cells co-expressing preferentially the
FGFR4-KLB but not FGFR1-KLB, FGF21 is unable to activate
the ERK1/2 response as compared to FGF19 and FGF1
(Figure 5B). This again indicates a potential difference in the
endocrine activities of FGF19 and FGF21. In the in vivo situation,
FGF19 may activate a broad type of tissues other than the liver,
while FGF21 may restrict to the tissues related to adipose property
or expressing predominantly the FGFR1-KLB.
Furthermore, ERK1/2 activation levels in response to graded
dosages of FGF19 and FGF21 in these cells indicated the half-
maximum concentrations for FGF19 and FGF21 were 10 and
6 ng/ml, which is 0.5 and 0.3 nM, respectively, given that the
molecular weight of both is about 20 kDa (Figure 6). These
concentrations are comparable to the recombinant FGF21 and
FGF19 used in other reports [53,54,56].
FGF21 activates predominantly the response of white
adipose tissue
To gain further insights into how FGF19 and FGF21, which
differ in specific FGFR-KLB interaction, differentially impact in
vivo endocrine metabolic effects, we determined their activities in
regulating the c-Fos gene expression, which is a marker in early
response to FGF19 stimulation [21], in different endocrine and
metabolic tissues including the liver and white adipose tissue that
Figure 2. Analyses of binding kinetic and affinity constant. T-
Rex 293 cells expressing inducible FGFR1 and constitutive KLB (A) and
hepatoma cells HR4 expressing FGFR4 and reduced level of KLB (B)
were maintained in DMEM medium with 5% FBS. Binding kinetic
analysis of radiolabeled FGF19 to the FGFR-KLB complexes on cell
surfaces were done as described in the Materials and Methods. The
binding affinity constant values were determined by the Scatchard plot.
doi:10.1371/journal.pone.0033870.g002
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are the two major types of tissues being implicated predominantly
in their actions. However, current reports are discrepant on
whether there is a liver effect of the FGF21 endocrine action. It is
also not clear whether there is an direct adipose effect of FGF19,
even though it was known that FGF19 exhibited anti-obesigenic
and anti-diabetic activities [58,59].
Recombinant FGF21 at 0.5 mg/Kg were injected into mouse
intraperitoneally as compared to FGF19 and vehicle PBS, and
after 20 min tissues were isolated for qPCR gene expression
analyses. FGF21 and FGF19 stimulated c-Fos mRNA expression
in mouse liver at 1.3 and 13.8 times over the PBS control,
respectively (Figure 7A). The liver response to FGF19 is more than
10 times that to FGF21. In contrast, FGF21 and FGF19
stimulated c-Fos mRNA expression in WAT at 5.1 and 4.3 times
over the control, respectively (Figure 7A). The response of WAT to
FGF19 is about 80% that to FGF21. The responses of other tissues
including pancreas, skeletal and heart muscles and hypothalamus
to FGF21 stimulation are relatively very low or undetectable
(Figure 7B). Note that the breast, which contains mostly the
adipose tissue, is the second highest responder. In all the cases, the
response of the liver to FGF21 is the lowest and close to vesicle
control. A thorough comparison of differential responses among all
aforementioned tissues to FGF21 and FGF19 would further
provide insights into their differential biological effects, which will
be undertaken in tissues from wild-type, KLB2/2, FGFR1
conditional ablation and FGF21 transgenic mice after crossbreed-
ing into a similar strain background.
Consistent with the acute c-Fos expression response, treatment
of mice with FGF21 for 20 minutes stimulates peak activation of
Erk1/2 [28] in the WAT (Figure 8A), but not in the liver and only
very weakly in hypothalamus and possibly skeletal muscle as well
(Figure 8A). These effects are substantially abolished in mice with
gene deletion for the cofactor KLB, as indicated by the percent
changes of pErk1/2 relative to total Erk1/2 (Figure 8A).
Furthermore, the conditional ablation of FGFR1 in adipocytes
in WAT by aP2 Cre (manuscript in preparation) also completely
abrogates the Erk1/2 activation by both FGF21 and FGF19
(Figure 8B), as compared to the FGFR1 floxed tissue and PBS
vehicle control. In the liver unaffected by the adipocyte-specific
ablation of FGFR1, Erk1/2 activation in response to FGF19
remains unchanged, while the response to FGF21 is relatively
insignificant or undetectable (Figure 8B), similar to the baseline
control from PBS as the delivery vehicle (not shown). This
response profile is also consistent with the differential tissue specific
expression of FGFR and KLB (Figure 9). The expression of
FGFR1 is high in WAT and hypothalamus. FGFR4 is only
expressed in the Liver, not in the WAT, hypothalamus and skeletal
muscle. In contrast, KLB is expressed high in both WAT and liver,
Figure 3. Dose-dependent differential binding of FGF21, FGF19 and FGF1 to FGFR1-KLB and FGFR4-KLB. (A) Competition ability of
FGF21 and FGF1 with FGF19 to bind FGFR-KLB. Graded concentrations as indicated for FGF21 (open square), FGF19 (filled triangle) and FGF1 (filled
circle) were added together with 2 ng/ml 125I-FGF19 to the cells expressing FGFR1-KLB (solid line) or FGFR4-KLB (dot line) after 30 ng/ml Tet
induction overnight, the remaining specific bindings of 125I-FGF19 were determined as described in Figure 1A. (B) Competition ability of FGF21 with
FGF1 to bind FGFR1-KLB. Graded concentrations as indicated for FGF21 (open square), FGF19 (not shown) and FGF1 (filled circle) were added
together with 2 ng/ml 125I-FGF1 to the cells expressing FGFR1-KLB (solid line) or FGFR4-KLB (Inset), the remaining specific bindings of 125I-FGF1 under
these conditions were determined as described above.
doi:10.1371/journal.pone.0033870.g003
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but low in the hypothalamus. Skeletal muscle expresses very low
level of FGFR1 predominantly as compared to the WAT and
hypothalamus. The rather weak response of hypothalamus to
exogenous FGF21 stimulation for 20 minutes may be due to the
blood-brain barrier and the low level of KLB expression (Figures 8
and 9). The levels of KLB and FGFR1 in the tissues from KLB2/
2 mice and WAT from FGFR1 CN mice, respectively, are below
the detection limit, the arbitrary cycle time of 34 in qPCR
analyses. Since FGF21 is preferentially expressed in the liver, our
results indicate not only the critical role of KLB and FGFR1 as the
biological receptor complex in transducing the signal of FGF21
and FGF19, but also a major emerging endocrine metabolic axis
from the liver to adipose tissues.
Discussion
As a single transmembrane protein, KLB plays an important
role in regulating bile acid synthesis, as revealed by genetic
ablation in normal condition [18,60]. KLB2/2 mice exhibited
elevated biosynthesis and secretion of bile acids through
upregulation of Cyp7a1 expression, a rate-limiting enzyme in
the bile acid anabolic pathway. This phenotype resembles those of
the FGFR4 and FGF15 (FGF19 in human) knockout mice [11,24].
Mice deficient in KL exhibited a variety of aging-like phenotypes
[19], many of which phenocopy those observed in FGF232/2
mice [61]. These studies uncovered the biological connections
among the conventional HS-FGFR, the KL family, and the
FGF19 subfamily that function in convergence in signal
transduction pathways for commitment of metabolic regulation
[9,10,56,62] rather than grossly the growth control. Like canonic
FGFs, the endocrine FGF19, FGF21 and FGF23 remain to signal
through FGFRs but only in the presence of the KL family. The
underlying mechanism for the KL family integration and the
consequence resulted from is still unclear. In this study, we found
that although FGF19 and FGF21 are unable to bind HS-FGFR
alone, they are able to bind through KLB with high affinity. The
binding of FGF19 and FGF21 to KLB and FGFR-KLB is not
affected by the presence of canonic member FGF1; similarly, the
binding of FGF1 to FGFR and FGFR-KLB is also completely
resistant to the presence of FGF19 and FGF21. The presence of
KLB confers even higher affinity for the FGF19 subfamily on the
HS-FGFR complex than KLB alone. These data suggest a mode
for the endocrine FGF-initiated FGFR signaling complex
formation that is different from that initiated by canonic FGFs.
We speculate that the binding sites on FGFR for FGF1 and
FGF19/21 may be not all the same, or may require additional
composite ones during the complex assemblage [16,63]. It is also
possible that FGF1 could reject the KLB from the complex, or that
KLB has no effect on FGF1-FGFR complex formation even when
present. The latter possibility appears to be supported by our data
Figure 4. Dose-dependent differential binding of FGF21, FGF19 and FGF1 to KLB or FGFR4 alone. (A) Interaction of FGF21, FGF19 and
FGF1 with KLB. Graded concentrations as indicated for FGF21 (open square), FGF19 (not shown) and FGF1 (filled circle) were added together with
2 ng/ml 125I-FGF19 to the cells expressing KLB alone, and the remaining specific bindings of 125I-FGF1 under these conditions were then determined.
(B) Competitive binding of FGF21 and FGF1 with FGF19 to FGFR4 alone. Graded concentrations as indicated for FGF21 (open square), FGF19 (not
shown) and FGF1 (filled circle) were added together with 2 ng/ml 125I-FGF19 to the cells expressing FGFR4 alone, and the remaining specific bindings
of 125I-FGF1 under these conditions were then determined.
doi:10.1371/journal.pone.0033870.g004
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that no additional cross-linked complexes were detected with
labeled FGF1 in the co-expression cells. This may explain why
FGF21/19 cannot compete with FGF1 binding even in presence
of KLB. On the other hand, the fact that FGF1 cannot compete
with FGF19 may indicate a FGFR-independent binding site of
FGF19/21 on KLB. Our results imply that KLB functions as a key
regulator of FGF19 and FGF21 not only by promoting their high-
affinity binding to and subsequent activation of FGFRs, but also
by determining their tissue-specific activity where KLB and
FGFRs are specifically co-expressed [17,21].
The differences in formation of the active canonic and non-
canonic complexes may underlie their downstream functional
divergence [1,4,64,65]. Further studies should shed light on the
mechanisms by which canonic FGFs and endocrine FGFs
coordinate local cell proliferation and metabolic function during
developmental stages and in pathophysiological circumstances.
This may be through regulating the ratio of FGF receptor to the
cofactor KLB, therefore, switching the end-effects between the cell
proliferation promoted by FGFR free of KLB and the cell
metabolism controlled by the integrative FGFR-KLB complex. It
is likely that the integration of KLB and endocrine FGFs in specific
tissues alters the major downstream signal effectors or pathways,
therefore, results in differential end-effects.
Although ileum FGF15/19 plays a primary role in negatively
regulating hepatic bile acids synthesis, there is so far no reported
adipose tissue phenotype in the FGF152/2 mice. However,
FGF19 (FGF15 in mice) administration or overexpression was
reported to have a profound impact on adiposity and diabetic
parameters, through yet unclear mechanisms in term of tissue and
molecular targets [21,58,59]. These effects are markedly similar to
those of FGF21 administration or overexpression through
regulating lipid, glucose and energy metabolism. Both FGF19
and FGF21 reach to target tissues through the endocrine
mechanism, the circulation. In particular, FGF19 has been
proposed to reach to the liver through portal vein from intestine;
therefore, it likely that through circulation, the adipose tissues will
be a secondary target of FGF19, even though a significant portion
of FGF19 from intestinal producing site may be trapped in the
liver through the dominant enterohepatic circulation. It is
conceivable that FGF19 may coordinate metabolism in the
adipose tissues and liver in response to the prandial stimulation.
This is also supported by our current data; however, more in vivo
studies are needed to address this important physiological
possibility.
FGF21 reportedly has no effect on expression of cyp7a1, a key
enzyme in hepatic bile acids synthesis (17), which is a hallmark of
FGFR4-KLB function in the liver; however, it plays notable roles
in lipid and glucose metabolism and thus is proposed as a novel
pharmacotherapy for obesity and diabetes. As of FGF19, the
mechanisms underlying the beneficial effects of FGF21 are also
unclear. Reports are discrepant on whether FGF21 has roles
directly in the liver for regulation of ketogenesis, triglycerides
clearance and glucose disposal, and on whether FGF21 stimulates
or inhibits lipolysis in white fat [17,27,31,33,44,47]. Reports
including ours (manuscript in preparation) are consistent on the
predominant co-expression of FGFR4-KLB in the liver, hepato-
cyte or hepatocyte-derived cells, and of FGFR1-KLB in adipose
tissues or mature adipocytes [17,21]. One of the keys to clarify
these important issues is to see how different tissues respond at the
early stage of FGF21 stimulation. In this study, we showed that
although FGF19 interacts with both binary FGFR1-KLB and
FGFR4-KLB with high affinity, FGF21 is able to bind only the
FGFR1-KLB but not FGFR4-KLB with a high affinity compa-
rable to that of FGF19 binding. This differential molecular
Figure 5. Differential activation of FGFRs and downstream MAPKs by FGF19 and FGF21. (A) Tyrosine phosphorylation of FGFR and
activation of ERK1/2 in engineered T-Rex 293 cells [4]. Expression of FGFR1 and FGFR4 was induced with 30 ng/ml Tet overnight. Cells were
stimulated with 100 ng/ml FGF21, FGF19 and FGF1 in presence of 1 mg/ml heparin, cell lysates in 16SDS sample buffer were used for immunoblot
analyses using antibodies as indicated. The identity of FGFR1 and FGFR4 was pre-determined by their respective antibodies (not showed). (B)
Responses of adipocytes and hepatocyte-like cells to the stimulation of FGF19 and FGF21. Mature 3T3-L1 adipocytes and HR4 hepatoma cells after
overnight serum-starvation were treated by FGF21, FGF19 and FGF1 at the concentrations as indicated, and cell lysates were used for immunoblot
analyses for MAPK activation as described above. The average relative activation level of Erk1/2 for each cell type under different stimulation
condition is expressed as the percentage to the peak activation of Erk1/2 treated with FGF1 after normalized as ratio of pErk1/2 to total Erk1/2.
doi:10.1371/journal.pone.0033870.g005
FGF21 Activates Preferentially Adipose FGFR1-KLB
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33870
interaction underlies the different tissue response profiles for
FGF19 and FGF21. FGF21 only effectively activates the responses
of the adipose tissue and adipocytes but not the liver where these
binary complexes are differentially present [17,28,44,52]; on the
other hand, FGF19 activates the responses of both the liver and
adipose tissue and the derived cells. These data are consistent with
our previous observation that mice with liver specific overexpres-
sion of constitutively active FGFR1 gain a suppression of bile acids
synthesis that is similar to the constitutively active FGFR4
overexpression [66]. Our results thus support a direct endocrine
metabolic role of FGF21 in fatty tissues but less likely in the liver,
while FGF19 may have also a role in fatty tissue, beyond the liver
as a primary target [59,67]. The reported effects of FGF21 on the
metabolic parameters in the liver are more likely from a secondary
indirect response of the liver to the direct metabolic effects of
FGF21 on other tissues, in particular the fatty tissues, in a
physiological concentration. This is consistent with the central
roles of the liver in monitoring, regulating and responding to the
ever-changing metabolic states of the whole body and many other
individual tissues. The results that FGF21 is primarily expressed in
the liver in response to fasting and pathological conditions such as
fatty accumulation and the obesity and diabetes [68,69], and that
FGF21 targets primarily the fatty tissues, indicate an emerging
endocrine metabolic pathway from the liver to fatty tissues in
regulating the lipid, glucose and energy metabolic homeostasis.
However, this doesn’t exclude a possibility that under certain
condition, the weakly expressed FGFR2 and/or FGFR3 beyond
the dominant FGFR4 may help the liver to respond to FGF21 in
an autocrine/paracrine fashion although likely at a much reduced
level. Other tissues, such as the breast, hypothalamus, pancreas
and muscle may also respond to FGF19/21 either directly or
indirectly under certain physiological and altered pathological
states. Whether FGF21 has a possible KLB-independent role in
vivo or whether FGF21 stimulates the responses of other tissues
where KLB expression is low or undetectable, as some studies have
suggested for FGF19, is now an open question.
Interestingly, although KLB2/2 mice exhibited bile acids
phenotype resembling that of FGFR42/2 and FGF152/2,
these mice have not been reported under normal diet condition a
metabolic abnormality phenocopying that of FGF212/2. This
does not exclude such a possibility under other pathological or diet
stress conditions. The combination of tissue expression specificity
and molecular receptor-cofactor interaction specificity determine
the eventual physiological outcome. KLB conceivably has
functions that overlap with as well as diverge from FGF21. These
functional difference and similarity will be balanced to present an
overt phenotype under different physiological and pathological
states. Tissue specific ablation approaches should be very useful to
dissect these difference and similarity issues.
We observed that the binding modes of the canonic FGF1 and
endocrine FGF19 and FGF21 to FGFRs likely possess similar as
well as different elements. The binding of FGF1 to FGFR-KLB
appears to be not affected by the presence of FGF19 or FGF21.
Furthermore, FGF1 binds FGFR and FGFR-KLB directly in the
Figure 6. Dose-dependent activity potential of FGF19 and
FGF21. Cells expressing endogenous FGFR4-KLB and FGFR1-KLB as
indicated were stimulated by different concentrations of FGF19 and
FGF21, respectively, for 10 minutes in 37uC culture. Cell lystes were then
used to determine the pERK1/2 levels under these conditions by
western-blotting. The pErk1/2 level for each cell type under each
stimulation condition is expressed as normalized arbitral units of ratio
of pErk1/2 to total Erk1/2. The half maximal effective concentration
(EC50) is then calculated in the logarithmic plot.
doi:10.1371/journal.pone.0033870.g006
Figure 7. Differential tissue-specific responses to FGF21 and
FGF19 as measured by the expression level of early responsive
gene c-Fos. Thirty age- and weight-matched mice (26365) were
fasted for 24 hrs with water freely available, and then injected
intraperitoneally with FGF21, FGF19 (0.5 mg/Kg body weight) and
PBS vesicle control as indicated. After 20 min, liver and adipose tissue
(A) and several other endocrine and metabolic tissues (B) were isolated
and processed for RNA purification. Quantitative PCR was used to assess
the expression of c-Fos in response to different treatments (n = 5).
doi:10.1371/journal.pone.0033870.g007
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Figure 8. Differential tissue-specific responses to FGF21 and FGF19 as measured by the activation level of Erk1/2. Endocrine FGF
treatment and tissue collection in mice were as described in Figure 7. The pErk1/2 levels in response to FGF21 in different tissues from wild-type and
KLB2/2 mice (A) as compared to PBS control, or in the adipose tissue and liver from the FGFR1 floxed (Flox) and CN mice (B) as compared to FGF19
and PBS were determined by immunoblot analyses. Data are representatives of 4–6 mice for each treatment scheme in each genotype group. The
average relative activation level of Erk1/2 for each type of tissue is expressed as percentage to the peak activation in WAT of the Flox mice treated
with FGF21, after normalized as ratio of pErk1/2 to total Erk1/2 (A) or ratio of pErk1/2 to b–Actin (B).
doi:10.1371/journal.pone.0033870.g008
Figure 9. Tissue-specific expression of FGFRs and KLB. Tissues as mentioned in Figure 8 were isolated from healthy C57/BL6, and total RNA
extracted was used for qPCR analyses of the expression of FGFR1–4 and KLB. Normalized expression levels were expressed as folds of difference
relative to that of b-Actin detected in each sample, and multiplied by 104 for graphic presentation. Data were presented as the mean of triplicates 6
S.D. Inset: small scale plot on y-axis of expression levels in skeletal muscle.
doi:10.1371/journal.pone.0033870.g009
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presence of HS motifs with high affinity, while FGF19 and FGF21
cannot bind directly to the HS-FGFR but in the presence of the
transmembrane KLB. It has been shown that the N- and C-
terminuses of FGF19 and FGF21 are required for the interaction
with FGFR and KLB, respectively; however, it is obvious that the
N-terminus alone is not sufficient for direct interaction with FGFR
without the presence of KLB [53,54,57]. These imply that the
high affinity binding of FGF19 and FGF21 to KLB, which has
been shown in a binary complex with FGFR that is ready to be
activated by the binding event [4], is likely the first and key
promoting step for the subsequent productive complex formation
through more interactions with FGFR that produce further higher
affinity and more stability. The integration of KLB into the HS-
FGFR for transducing the FGF19 and FGF21 stimulation across
the plasma membrane is therefore a hallmark event for their
metabolic effects. This integration was visualized by the presence
of several possible cross-linking bands. It would be interesting to
know how the divergence and specificity in the intracellular
phosphorylation and selection of signaling relay adaptors are
resulted from the extracellular integration.
Materials and Methods
Ethics Statement
All mice were housed in the Program of Animal Resources in
the Institute of Biosciences and Technology, and were handled in
accordance with the principles and procedure of the Guide for the Care and
Use of Laboratory Animals. All experimental procedures were
approved by the Institute of Biosciences and Technology
Institutional Animal Care and Use Committee (IBT IACUC)
with a protocol #10022 entitled ‘‘BetaKlotho-FGFR in the liver’’.
Expression plasmid constructs
Human full-length FGFR1bIIIC (NM_023105) and FGFR4
(AAM13666) in the Tet-on pcDNA4/TO mammalian inducible
expression vector, and murine KLB (NM_031180) in pEF1a (a gift
from Dr. Kuro-O M) [9] were described previously [4]. Human
FGF19 and murine FGF21 in pET28 with 66His tag at the N-
terminus were expressed in BL21 DE3 E. coli, and refolded from
inclusion body or directly purified from soluble fraction on Ni-
chelating Sepharose chromatography using AKTApurifier (GE
HealthCare, MA). Recombinant human FGF21 with a N-terminal
66His tag with an activity equal to our preparation of murine
FGF21 as determined in our ERK activation assay (Figure 6) was
from Dr. Xiaokun Li (Wenzhou Medical College, China).
Cell lines
The establishment, maintaining and protein expression induc-
tion of the tetracycline (Tet)-inducible T-Rex-293 cell lines
(Invitrogen, CA) expressing the iFGFR1-cKLB, iFGFR4-cKLB,
iFGFR1, iFGFR4 or cKLB were described previously [4]. The
generation and maintaining of the HR4 hepatoma cell line was
also described in our previous study with FGFR42/2 and DEN
hepatoma model [4,70].
Mouse tissues
The KLB2/2 mouse line with an inactivating insertion in the
first intron was obtained by gene-trap technology (TIGM, Texas).
The homozygous C57/BL6 mice exhibited an increase in hepatic
bile acids and about 35% less survival rate than expected, similar
to that previously reported [60]. Mice deficient in FGFR1 in
specifically the adipose tissue (AdiFGFR1) were generated by using
FGFR1f/f (Flox) and aP2-Cre mice [71,72] (manuscript in
preparation). The aP2 promoter is relatively adipocyte-specific.
AdiFGFR1 conditional null (CN) mice were obtained from
FGFR1f/f mice and aP2-Cre+/w mice, and then breeding with
C57/BL6 for more than five generations. qPCR results indicate
that FGFR1 was reduced to nearly an undetectable level in
adipocytes in WAT.
The male C57/BL6 mice at 5 or 6 weeks old were provided
standard feeding and water ad libitum according to the protocols
approved by the Institutional Animal Care and Use Committee.
Before injection mice were fasted overnight by withdrawal of food
with water still available. Pure recombinant FGF19 or FGF21 at
0.5 mg/Kg or vehicle (16PBS) were then injected intraperitone-
ally into six mice in each group. After 20 min, mice were
sacrificed, and the left lobes of the livers, gonadal adipose tissues,
hypothalamus, pancreas, skeletal muscle, etc., were isolate, and
frozen at 280uC.
Quantitative PCR analyses
Total RNA was isolated from cells or tissues using Ultraspec
RNA Isolation reagents (Biotecx Laboratories, Houston, TX).
Equal amounts of total RNA from five mice were pooled and then
5 ug was subjected to the reverse transcription. Primers 59-
ACTCCTTCTCCAGCATGGGCTC and 59-AGTTGAATC-
TGTCTCCGCTTGGAG were used to quantify the expression
level of c-Fos. Primers pairs 59-CTGAAGGAGGGTCATC-
GAAT and 59-GTCCAGGTCTTCCACCAACT, 59-CAC-
CACGGACAAAGAGATTG and 59-TGTCAACCATGCAGA-
GTGAA, 59-AGATGCTGAAAGATGATGCG and 59-AT-
GATGTTCTTGTGCTTGCC, and 59-CAGAGGCCTTTGG-
TATGGAT and 59-AGGTCTGCCAAATCCTTGTC were for
mouse FGFR1, FGFR2, FGFR3 and FGFR4, respectively.
Primers 59-CAGAGAAGGAGGAGGTGAGG and 59-CAG-
CACCTGCCTTAAGTTGA were for mouse KLB. These primer
pairs were designed by the real-time PCR (TagMan) primer design
program from GenScript, all with the Tm of 59uC and the
amplicon length of 80–150 bp. Relative gene expression was
measured by real-time PCR with 40 cycles using the SYBR Green
JumpStart Taq Ready Mix (Sigma) on the Stratagene Mx3000P
qPCR system. All measurements were done in triplicate, and
relative amounts of mRNA were calculated by the comparative
threshold (Ct) cycle method using b-actin as the internal control,
and presented as mean6S.E.M using two-tailed unpaired
Student’s t-test. For the comparison of expression levels of FGFRs
and KLB across all different tissues examined, the threshold cycle
times were subtracted with 34, which was determined as the cycle
limit for detection. Normalized expression levels were expressed as
arbitrary folds of difference by dividing by that of b-Actin detected
in each sample, and multiplied by 104 for graphic presentation.
Data were presented as the mean of triplicates 6 S.D.
Immunoblot analyses
Cells after treatment were lysed in 16 SDS sample buffer.
Alternatively, cells were lysed in modified cold RIPA buffer of
20 mM Tris-HCl, pH 7.2, 50 mM NaCl, 1% NP-40, 0.1%
sodium deoxycholate, 2 mM sodium orthovanadate (pre-oxidized
by H2O2 prior to use) and 2 mM NaF, and before use, 1 pill each
of protease inhibitors and phosphatase inhibitors (Roche, IN) per
10 ml were added. Supernatants after centrifugation were used to
perform immunoprecipitation with antibodies and protein A/G
agarose. Whole cell lysate supernatants or immunoprecipitates
were separated by 10% SDS-PAGE and transferred onto
nitrocellulose membranes. The membrane was probed with the
antibodies against FGFR4, KLB, ERK and phospho-ERK1/2
(Santa Cruz Biotechnology, CA), and pTyr (Cell Signaling
Technology, Inc). For sequential blotting, the wet membranes
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were stripped by using a solution of 40% methanol and 2% acetic
acid for 30 min.
Cell surface receptor binding, cross-linking and binding
constant determination
125Iodine labeling of FGF1 and subsequent heparin-sepharose
purification were as described [73]. Active recombinant His-
tagged FGF19 after iodination was purified by Ni-Chelating
sepharose chromatography following the established procedure
[4]. Binding was done under specific conditions designed to
support specific binding [73] on the surface of T-Rex 293 cells
expressing different combinations of FGFR1, FGFR4 and KLB.
Specific binding of 125I-FGF to the FGFR ectodomain was
distinguished and extracted from non-specific binding, and
confirmed by covalent affinity crosslinking as described [4,74].
Scatchard binding kinetic analysis was done in a range of 0.0625
to 8 ng/ml 125I-FGF19 on the FGFR-KLB complexes expressed
on cell surfaces at 4uC for 30 min. Non-specific and matrix
binding was less than 10% of total determined in the presence of
250 mg/ml heparin and 30-fold unlabeled FGF. Affinity constant
Kd was estimated by linear least square regression analysis
[55,73]. Experiments were repeated at least three times with
samples from at least three independent preparations.
Reproducibility and statistical analysis
Unless otherwise indicated, each experiment was reproduced at
least three times independently with triplicates within each
experiment. A representative of three or more experiments is
shown in micrographs. Where indicated, the mean and standard
deviation (S.E.M) were determined by student t-test.
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